Department of Ophthalmology, Rheinisch-Westfälische Technische Hochschule Aachen University, Germany.
Am J Ophthalmol. 2012 Mar;153(3):454-459.e2. doi: 10.1016/j.ajo.2011.08.009. Epub 2011 Oct 11.
To compare hyperbaric oxygen treatment combined with hemodilution with hemodilution only in central retinal artery obstruction.
Retrospective, nonrandomized case series.
We reviewed records of all our patients diagnosed with central retinal artery obstruction between 1997 and 2010. In these patients, hyperbaric oxygen and hemodilution therapy had been administered routinely (oxygen group). Where hyperbaric oxygenation could not be performed, patients were underwent hemodilution only (control group). Patients with presenting visual acuity (VA) of up to 20/200 within 12 hours of onset were included in our analysis. Exclusion criteria included cilioretinal vessels or arteritic occlusion.
The oxygen group comprised 51 patients, and the control group comprised 29 patients. Mean baseline VA was counting fingers (oxygen group) and 20/1000 (control group; P = .1). Most other potential confounders, including duration of symptoms, also did not differ significantly at baseline. In the oxygen group, mean VA improvement was 3 lines (P < .0001). This was sustained over a follow-up of 3 months (P = .01). In the control group, mean improvement was 1 line (P = .23 at discharge, P = .17 at follow-up). Differences between both groups were not significant (P = .07 at discharge, P = .26 at follow-up). The number of patients gaining 3 lines or more was 38.0% versus 17.9% at discharge (P = .06) and 35.7% versus 30.8% at follow-up (P = .76).
We saw significant VA improvement after the combined treatment, but not when using hemodilution only. Confirming superiority of the combination treatment requires a randomized, prospective trial. A high number of nonresponders highlights the need to improve our understanding and treatment of hypoxia-related metabolic insults after central retinal artery obstruction.
比较高压氧治疗联合血液稀释与单纯血液稀释治疗视网膜中央动脉阻塞的效果。
回顾性、非随机病例系列研究。
我们回顾了 1997 年至 2010 年间所有被诊断为视网膜中央动脉阻塞的患者的病历。这些患者常规接受高压氧和血液稀释治疗(氧气组)。如果无法进行高压氧治疗,则仅接受血液稀释治疗(对照组)。我们将发病 12 小时内视力达到 20/200 的患者纳入分析。排除标准包括睫状视网膜血管或动脉炎性阻塞。
氧气组有 51 例患者,对照组有 29 例患者。基线视力均值为指数(氧气组)和 20/1000(对照组;P=0.1)。大多数其他潜在混杂因素,包括症状持续时间,在基线时也没有显著差异。在氧气组中,平均视力提高了 3 行(P<0.0001)。这一改善在 3 个月的随访中持续存在(P=0.01)。在对照组中,平均改善为 1 行(出院时 P=0.23,随访时 P=0.17)。两组之间的差异无统计学意义(出院时 P=0.07,随访时 P=0.26)。有 38.0%的患者在出院时视力提高了 3 行或以上,而对照组为 17.9%(P=0.06);在随访时,分别为 35.7%和 30.8%(P=0.76)。
我们观察到联合治疗后视力显著改善,但单纯血液稀释治疗则不然。要证实联合治疗的优势,需要进行一项随机、前瞻性试验。大量无反应者突出表明,我们需要提高对视网膜中央动脉阻塞后与缺氧相关的代谢损伤的认识并改进其治疗方法。